Tailored axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer patients is safe: 3-year follow-up of the MARI protocol
Van Loevezijn, A., van der Noordaa, M.E.M., van Duijnhoven, F., Groen, E.J., Stokkel, M.P.M., Loo, C.E., Elkhuizen, P., Russell, N.S., Vrancken-Peeters, M.J.Volume:
138
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(20)30538-4
Date:
October, 2020
File:
PDF, 75 KB
2020